Last
Update:
September 05, 2015
 Documents
identified with this icon are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader
-
POSTER
Safety and efficacy of maraviroc-raltegravir combination following 6 months
induction with maraviroc-raltegravir-tenofovir-emtricitabine in naïve
HIV-1-infected patients with CCR5 virus: interim analysis of the No Nuc No
Boost study
L. Cotte1, J. Durant, C. Brochier, P. André
Poster
Abstract
-
Safety and efficacy of
maraviroc in CCR5-tropic HIV-1-infected children aged 2 to < 18 years
C. Giaquinto, L. Keet, C. Fortuny, et al
Abstract
-
Maraviroc (MVC)
intensification can activate NFkB through CCR5 and the expression of its
target genes in resting CD4+ T cells in suppressed HIV-1-infected patients
N. Madrid-Elena, B. Hernandez-Novoa, L. Garcia-Bermejo, S. Moreno
Abstract
-
Update from Study
A4001031: maraviroc pharmacokinetics in CCR5-tropic HIV-1-infected children
aged 2 to < 18 years
M. Vourvahis, L. McFadyen, T. Checchio, et al
Abstract
-
Modelling HIV PrEP in
humanized mice: pharmacokinetic studies on antiretroviral drugs raltegravir,
tenofovir and maraviroc
R. Akkina, M. Veselinovic C.P. Ne et al
Abstract
|
7th IAS Conference
on HIV Pathogenesis, Treatment and Prevention
Maraviroc
Main Page
Main
New/Newsworthy